NCT05279131View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis

PHASE3CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

December 28, 2022

Study Completion Date

December 28, 2022

Conditions
Keratosis, Actinic
Interventions
DRUG

Tirbanibulin ointment 1%

Applied topically for 5 days over a field of approximately 100 cm\^2 on the face or balding scalp with AK.

Trial Locations (7)

33172

Almirall Investigation Site 3, Sweetwater

60008

Almirall Investigation Site 5, Rolling Meadows

71913

Almirall Investigation Site 7, Hot Springs

77845

Almirall Investigational Site 1, College Station

78213

Almirall Investigation Site 2, San Antonio

78759

Almirall Investigation Site 4, Austin

92024

Almirall Investigation Site 6, Encinitas

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
lead

Almirall, S.A.

INDUSTRY